Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02410551|
Recruitment Status : Terminated
First Posted : April 7, 2015
Last Update Posted : January 25, 2017
|Condition or disease||Intervention/treatment||Phase|
|Myeloproliferative Diseases||Drug: Pacritinib Drug: Busulfan Behavioral: Questionnaires Behavioral: Phone Calls Procedure: Allogeneic Stem Cell Transplantation Drug: Fludarabine||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||4 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pacritinib Prior to Transplant for Patients With Myeloproliferative Neoplasms (MPN)|
|Actual Study Start Date :||June 15, 2015|
|Actual Primary Completion Date :||January 20, 2017|
|Actual Study Completion Date :||January 20, 2017|
Experimental: Pacritinib + Allogeneic Stem Cell Transplantation
Participants start Pacritinib 200 mg by mouth twice a day. Participants proceed to transplant after 60 days of Pacritinib but not more than 180 days. Pacritinib stopped 21 days prior to starting preparative regimen for standard of care stem cell transplantation (SOC Allo TP). SOC transplant conditioning with Fludarabine and Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days. Questionnaires about symptoms and quality of life completed at baseline, 1, 3, 6, and 12 months after transplant. Phone calls made by study staff to participant on second and third week of each month.
200 mg by mouth twice a day for 60 days.Drug: Busulfan
Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days.
Other Names:Behavioral: Questionnaires
Questionnaires completed at baseline, 1, 3, 6, and 12 months after transplant.
Other Name: SurveysBehavioral: Phone Calls
Phone calls made by study staff to participant on second and third week of each month.Procedure: Allogeneic Stem Cell Transplantation
Allogeneic stem cell transplantation (Allo TP) 60 days after starting Pacritinib but not more than 180 days.
Other Name: Stem cell transplantDrug: Fludarabine
Fludarabine taken along with Busulfan as per standard of care as preparative regimen for allogeneic stem cell transplantation (Allo TP).
- Progression-free Survival (PFS) [ Time Frame: 1 year ]Progression-free survival defined as the time of stem-cell transplant to the time of death or disease progression.
- Neutrophil Engraftment [ Time Frame: 3 weeks after transplant ]Neutrophil engraftment defined as a sustained ANC > 0.5 x 109/L for 3 consecutive days and evidence of donor chimerism by D+28.
- Platelet Engraftment [ Time Frame: 1 month ]Platelet engraftment defined as a sustained first of three consecutive laboratory values of platelet ³ 20x109/L with no platelet transfusions administered for 7 consecutive days.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02410551
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Uday Popat, MD||M.D. Anderson Cancer Center|